Last reviewed · How we verify

NCT04930224

Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients

Completed Last updated 23 June 2021
What this trial tests

trial testing The effect of GPER-1 on the formation of diabetic retinopathy in Diabetes Mellitus in 120 participants. Completed in 25 April 2020.

Timeline
1 July 2019
Primary endpoint
31 January 2020
25 April 2020

Quick facts

Lead sponsorKahramanmaras Sutcu Imam University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment120
Start date1 July 2019
Primary completion31 January 2020
Estimated completion25 April 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kahramanmaras Sutcu Imam University

Who can join

Adults 35 to 65, any sex, with Diabetes Mellitus or Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, comparative, cross-sectional study

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Kahramanmaras Sutcu Imam University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04930224.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing